{"protocolSection":{"identificationModule":{"nctId":"NCT01165229","orgStudyIdInfo":{"id":"113077"},"secondaryIdInfos":[{"id":"2009-015791-94","type":"EUDRACT_NUMBER"},{"id":"2009","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2009"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older","officialTitle":"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older"},"statusModule":{"statusVerifiedDate":"2020-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-08-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-07-24","type":"ACTUAL"},"completionDateStruct":{"date":"2015-07-24","type":"ACTUAL"},"studyFirstSubmitDate":"2010-07-15","studyFirstSubmitQcDate":"2010-07-15","studyFirstPostDateStruct":{"date":"2010-07-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-05-09","resultsFirstSubmitQcDate":"2017-11-10","resultsFirstPostDateStruct":{"date":"2017-11-20","type":"ACTUAL"},"dispFirstSubmitDate":"2013-08-22","dispFirstSubmitQcDate":"2013-08-22","dispFirstPostDateStruct":{"date":"2013-08-30","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-04-15","lastUpdatePostDateStruct":{"date":"2020-04-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.\n\nTwo studies (Zoster-006 \\[NCT01165177\\] and Zoster-022 \\[NCT01165229\\]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.","detailedDescription":"This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy (HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) separately."},"conditionsModule":{"conditions":["Herpes Zoster","Herpes Zoster Vaccine"],"keywords":["Immunogenicity","Subjects 70 years and older","Efficacy","Herpes Zoster","Safety","Adults","Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":14819,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Zoster vaccine group","type":"EXPERIMENTAL","description":"Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule","interventionNames":["Biological: Herpes Zoster Vaccine GSK1437173A"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","description":"Subjects will receive NaCl solution placebo according to a 0, 2-month schedule","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster Vaccine GSK1437173A","description":"Intramuscular injection","armGroupLabels":["Zoster vaccine group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Intramuscular injection.","armGroupLabels":["Placebo group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Any Episodes of Herpes Zoster (HZ)","description":"Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)","description":"Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ","description":"Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"}],"secondaryOutcomes":[{"measure":"Number of Subjects With Post-herpetic Neuralgia (PHN)","description":"PHN cases in the mTVc.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Days With Severe 'Worst' HZ-associated Pain","description":"Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations","description":"The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With Overall Mortality and HZ-related Mortality","description":"The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With Confirmed HZ Episode Related Hospitalizations","description":"Incidence of overall and HZ-related hospitalizations during the study.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With HZ Related Complications","description":"Incidence of HZ complications during the study in subjects with confirmed HZ.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects Receiving Pain Medication Associated With HZ","description":"Incidence of use of pain medications throughout the study","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Days With Pain Medication Associated With HZ","description":"Incidence of reduction of duration of pain medication associated with HZ throughout the study.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","timeFrame":"Within the 30 days (Days 0-29) after each vaccination"},{"measure":"Number of Subjects With Any and Related Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"From Month 0 to Month 14"},{"measure":"Number of Subjects With Fatal Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication","description":"The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated","timeFrame":"During the entire study period (3 to 5 year period following day 0)"},{"measure":"Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)","description":"Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Number of Subjects With Any and Related Medically Attended Visits","description":"Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.","timeFrame":"From Month 0 to Month 8 post-vaccination"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA","description":"Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ","description":"Occurrence of PHN during the entire study period in all subjects with confirmed HZ.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.","description":"The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.","description":"Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA","description":"Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","timeFrame":"Within 30 days (Days 0 - 29) after each vaccination"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs","description":"Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.","timeFrame":"From Month 0 to Month 14"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs","description":"Fatal SAEs during the entire study period in subjects ≥ 70 YOA.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs","description":"Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.","timeFrame":"During the entire study period (3 to 5 year period following Day 0)"},{"measure":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits","description":"Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.","timeFrame":"From Month 0 to Month 8 post-vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes will comply with the requirements of the protocol.\n* Written informed consent obtained from the subject.\n* A male or female aged 70 years or older at the time of the first vaccination.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy History of HZ.\n* Previous vaccination against varicella or HZ.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation.\n* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.\n* Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period.\n* Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine.\n* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.\n* Acute disease and/or fever at the time of enrolment.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.","healthyVolunteers":true,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Mesa","state":"Arizona","zip":"85213","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85050","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Tucson","state":"Arizona","zip":"85704","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"GSK Investigational Site","city":"Spring Valley","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"GSK Investigational Site","city":"Vista","state":"California","zip":"92083","country":"United States","geoPoint":{"lat":33.20004,"lon":-117.24254}},{"facility":"GSK Investigational Site","city":"Clearwater","state":"Florida","zip":"33761","country":"United States","geoPoint":{"lat":27.96585,"lon":-82.8001}},{"facility":"GSK Investigational Site","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"GSK Investigational Site","city":"Jacksonville","state":"Florida","zip":"32205","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"GSK Investigational Site","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"GSK Investigational Site","city":"West Palm Beach","state":"Florida","zip":"33409","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"GSK Investigational Site","city":"Meridian","state":"Idaho","zip":"83642","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"GSK Investigational Site","city":"Overland Park","state":"Kansas","zip":"66212","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"GSK Investigational Site","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"GSK Investigational Site","city":"Baltimore","state":"Maryland","zip":"21209","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"GSK Investigational Site","city":"Columbia","state":"Maryland","zip":"21045","country":"United States","geoPoint":{"lat":39.24038,"lon":-76.83942}},{"facility":"GSK Investigational Site","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89104","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89119","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Edison","state":"New Jersey","zip":"08817","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"facility":"GSK Investigational Site","city":"Somers Point","state":"New Jersey","zip":"08244","country":"United States","geoPoint":{"lat":39.31762,"lon":-74.5946}},{"facility":"GSK Investigational Site","city":"Cary","state":"North Carolina","zip":"27518","country":"United States","geoPoint":{"lat":35.79154,"lon":-78.78112}},{"facility":"GSK Investigational Site","city":"Charlotte","state":"North Carolina","zip":"28209","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"GSK Investigational Site","city":"Hickory","state":"North Carolina","zip":"28602","country":"United States","geoPoint":{"lat":35.73319,"lon":-81.3412}},{"facility":"GSK Investigational Site","city":"Salisbury","state":"North Carolina","zip":"28144","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"GSK Investigational Site","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"GSK Investigational Site","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"GSK Investigational Site","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"GSK Investigational Site","city":"Wadsworth","state":"Ohio","zip":"44281","country":"United States","geoPoint":{"lat":41.02561,"lon":-81.72985}},{"facility":"GSK Investigational Site","city":"Carnegie","state":"Pennsylvania","zip":"15106","country":"United States","geoPoint":{"lat":40.40868,"lon":-80.08339}},{"facility":"GSK Investigational Site","city":"Pleasant Hills","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.33563,"lon":-79.96061}},{"facility":"GSK Investigational Site","city":"Uniontown","state":"Pennsylvania","zip":"15401","country":"United States","geoPoint":{"lat":39.90008,"lon":-79.71643}},{"facility":"GSK Investigational Site","city":"Greer","state":"South Carolina","zip":"29650","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"GSK Investigational Site","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"GSK Investigational Site","city":"Bristol","state":"Tennessee","zip":"37620","country":"United States","geoPoint":{"lat":36.59511,"lon":-82.18874}},{"facility":"GSK Investigational Site","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"GSK Investigational Site","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"GSK Investigational Site","city":"Arlington","state":"Virginia","zip":"22203","country":"United States","geoPoint":{"lat":38.88101,"lon":-77.10428}},{"facility":"GSK Investigational Site","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"GSK Investigational Site","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"GSK Investigational Site","city":"Winchester","state":"Virginia","zip":"22601","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"GSK Investigational Site","city":"Renton","state":"Washington","zip":"98057","country":"United States","geoPoint":{"lat":47.48288,"lon":-122.21707}},{"facility":"GSK Investigational Site","city":"Glebe","state":"New South Wales","zip":"2037","country":"Australia","geoPoint":{"lat":-33.87884,"lon":151.18426}},{"facility":"GSK Investigational Site","city":"Maroubra","state":"New South Wales","zip":"2035","country":"Australia","geoPoint":{"lat":-33.95,"lon":151.23333}},{"facility":"GSK Investigational Site","city":"Umina","state":"New South Wales","zip":"2257","country":"Australia"},{"facility":"GSK Investigational Site","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"GSK Investigational Site","city":"Wollongong","state":"New South Wales","zip":"2522","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"GSK Investigational Site","city":"Caboolture","state":"Queensland","zip":"4510","country":"Australia","geoPoint":{"lat":-27.08465,"lon":152.9511}},{"facility":"GSK Investigational Site","city":"Kippa-Ring","state":"Queensland","zip":"4021","country":"Australia","geoPoint":{"lat":-27.22586,"lon":153.0835}},{"facility":"GSK Investigational Site","city":"Geelong","state":"Victoria","zip":"3220","country":"Australia","geoPoint":{"lat":-38.14711,"lon":144.36069}},{"facility":"GSK Investigational Site","city":"Ivanhoe","state":"Victoria","zip":"3079","country":"Australia","geoPoint":{"lat":-37.76903,"lon":145.04308}},{"facility":"GSK Investigational Site","city":"Belo Horizonte","state":"Minas Gerais","zip":"30150-221","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"GSK Investigational Site","city":"Curitiba/Paraná","state":"Paraná","zip":"80810-050","country":"Brazil"},{"facility":"GSK Investigational Site","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90035003","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"GSK Investigational Site","city":"Curitiba/PR","zip":"80240-280","country":"Brazil"},{"facility":"GSK Investigational Site","city":"São Paulo","zip":"04038 002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"GSK Investigational Site","city":"São Paulo","zip":"04266-010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"GSK Investigational Site","city":"São Paulo","zip":"04312903","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"GSK Investigational Site","city":"Vancouver","state":"British Columbia","zip":"V5Z 1M9","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"GSK Investigational Site","city":"Victoria","state":"British Columbia","zip":"V8V 3P9","country":"Canada","geoPoint":{"lat":48.4359,"lon":-123.35155}},{"facility":"GSK Investigational Site","city":"Bay Roberts","state":"Newfoundland and Labrador","zip":"A0A 1G0","country":"Canada","geoPoint":{"lat":47.59989,"lon":-53.26478}},{"facility":"GSK Investigational Site","city":"Halifax","state":"Nova Scotia","zip":"B3K 6R8","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"GSK Investigational Site","city":"Truro","state":"Nova Scotia","zip":"B2N 1L2","country":"Canada","geoPoint":{"lat":45.36685,"lon":-63.26538}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M4S 1Y2","country":"Canada","geoPoint":{"lat":43.65333,"lon":-79.38389}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M9W 4L6","country":"Canada","geoPoint":{"lat":43.65333,"lon":-79.38389}},{"facility":"GSK Investigational Site","city":"Woodstock","state":"Ontario","zip":"N4S 5P5","country":"Canada","geoPoint":{"lat":43.13339,"lon":-80.7497}},{"facility":"GSK Investigational Site","city":"Gatineau","state":"Quebec","zip":"J8Y 6S8","country":"Canada","geoPoint":{"lat":45.47723,"lon":-75.70164}},{"facility":"GSK Investigational Site","city":"Mirabel","state":"Quebec","zip":"J7J 2K8","country":"Canada","geoPoint":{"lat":45.65008,"lon":-74.08251}},{"facility":"GSK Investigational Site","city":"Pointe-Claire","state":"Quebec","zip":"H9R 4S3","country":"Canada","geoPoint":{"lat":45.44868,"lon":-73.81669}},{"facility":"GSK Investigational Site","city":"Québec","state":"Quebec","zip":"G1E 7G9","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"GSK Investigational Site","city":"Québec","state":"Quebec","zip":"G1W 4R4","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"GSK Investigational Site","city":"Sherbrooke","state":"Quebec","zip":"J1H 2G2","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"GSK Investigational Site","city":"Trois-Rivières","state":"Quebec","zip":"G8T 7A1","country":"Canada","geoPoint":{"lat":46.34515,"lon":-72.5477}},{"facility":"GSK Investigational Site","city":"Brno","zip":"662 10","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"GSK Investigational Site","city":"České Budějovice","zip":"370 04","country":"Czechia","geoPoint":{"lat":48.97447,"lon":14.47434}},{"facility":"GSK Investigational Site","city":"Hradec Králové","zip":"500 01","country":"Czechia","geoPoint":{"lat":50.20923,"lon":15.83277}},{"facility":"GSK Investigational Site","city":"Tallinn","zip":"13619","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"GSK Investigational Site","city":"Tartu","zip":"50106","country":"Estonia","geoPoint":{"lat":58.38062,"lon":26.72509}},{"facility":"GSK Investigational Site","city":"Espoo","zip":"02230","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"GSK Investigational Site","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"GSK Investigational Site","city":"Helsinki","zip":"00930","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"GSK Investigational Site","city":"Jarvenpaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"GSK Investigational Site","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"GSK Investigational Site","city":"Oulu","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"GSK Investigational Site","city":"Pori","zip":"28100","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"GSK Investigational Site","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"GSK Investigational Site","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"GSK Investigational Site","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"GSK Investigational Site","city":"Angers","zip":"49000","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"GSK Investigational Site","city":"Château-Gontier","zip":"53200","country":"France","geoPoint":{"lat":47.82705,"lon":-0.70512}},{"facility":"GSK Investigational Site","city":"Cherbourg","zip":"50100","country":"France","geoPoint":{"lat":49.63984,"lon":-1.61636}},{"facility":"GSK Investigational Site","city":"Clermont-Ferrand","zip":"63003","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"facility":"GSK Investigational Site","city":"Laval","zip":"53000","country":"France","geoPoint":{"lat":48.07247,"lon":-0.77019}},{"facility":"GSK Investigational Site","city":"Laval","zip":"53100","country":"France","geoPoint":{"lat":48.07247,"lon":-0.77019}},{"facility":"GSK Investigational Site","city":"Montrevault","zip":"49110","country":"France","geoPoint":{"lat":47.26145,"lon":-1.04579}},{"facility":"GSK Investigational Site","city":"Muret","zip":"31600","country":"France","geoPoint":{"lat":43.45998,"lon":1.32541}},{"facility":"GSK Investigational Site","city":"Nantes","zip":"44300","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"GSK Investigational Site","city":"Rosiers-d'Égletons","zip":"19300","country":"France","geoPoint":{"lat":45.37738,"lon":2.00813}},{"facility":"GSK Investigational Site","city":"Saint Cyr Sur Loir","zip":"37540","country":"France"},{"facility":"GSK Investigational Site","city":"Segré","zip":"49500","country":"France","geoPoint":{"lat":47.68672,"lon":-0.87268}},{"facility":"GSK Investigational Site","city":"Soulaines-sur-Aubance","zip":"49610","country":"France","geoPoint":{"lat":47.3643,"lon":-0.5229}},{"facility":"GSK Investigational Site","city":"Tours","zip":"37100","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"facility":"GSK Investigational Site","city":"Deggingen","state":"Baden-Wurttemberg","zip":"73326","country":"Germany","geoPoint":{"lat":48.5971,"lon":9.71891}},{"facility":"GSK Investigational Site","city":"Güglingen","state":"Baden-Wurttemberg","zip":"74363","country":"Germany","geoPoint":{"lat":49.06642,"lon":9.00175}},{"facility":"GSK Investigational Site","city":"Mannheim","state":"Baden-Wurttemberg","zip":"68161","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"GSK Investigational Site","city":"Tübingen","state":"Baden-Wurttemberg","zip":"72074","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"GSK Investigational Site","city":"Wangen","state":"Baden-Wurttemberg","zip":"88239","country":"Germany","geoPoint":{"lat":47.6895,"lon":9.83247}},{"facility":"GSK Investigational Site","city":"Weinheim","state":"Baden-Wurttemberg","zip":"69469","country":"Germany","geoPoint":{"lat":49.54887,"lon":8.66697}},{"facility":"GSK Investigational Site","city":"Dachau","state":"Bavaria","zip":"85221","country":"Germany","geoPoint":{"lat":48.26,"lon":11.43402}},{"facility":"GSK Investigational Site","city":"Künzing","state":"Bavaria","zip":"94550","country":"Germany","geoPoint":{"lat":48.66667,"lon":13.08333}},{"facility":"GSK Investigational Site","city":"Munich","state":"Bavaria","zip":"80339","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"GSK Investigational Site","city":"Rednitzhembach","state":"Bavaria","zip":"91126","country":"Germany","geoPoint":{"lat":49.30095,"lon":11.07997}},{"facility":"GSK Investigational Site","city":"Wallerfing","state":"Bavaria","zip":"94574","country":"Germany","geoPoint":{"lat":48.68416,"lon":12.88035}},{"facility":"GSK Investigational Site","city":"Würzburg","state":"Bavaria","zip":"97070","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"GSK Investigational Site","city":"Potsdam","state":"Brandenburg","zip":"14467","country":"Germany","geoPoint":{"lat":52.39886,"lon":13.06566}},{"facility":"GSK Investigational Site","city":"Flörsheim","state":"Hesse","zip":"65439","country":"Germany","geoPoint":{"lat":50.01311,"lon":8.42779}},{"facility":"GSK Investigational Site","city":"Frankfurt am Main","state":"Hesse","zip":"60389","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"GSK Investigational Site","city":"Duelmen","state":"Lower Saxony","zip":"48249","country":"Germany"},{"facility":"GSK Investigational Site","city":"Cologne","state":"North Rhine-Westphalia","zip":"51069","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"GSK Investigational Site","city":"Essen","state":"North Rhine-Westphalia","zip":"45355","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"GSK Investigational Site","city":"Essen","state":"North Rhine-Westphalia","zip":"45359","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"GSK Investigational Site","city":"Goch","state":"North Rhine-Westphalia","zip":"47574","country":"Germany","geoPoint":{"lat":51.67873,"lon":6.15895}},{"facility":"GSK Investigational Site","city":"Witten","state":"North Rhine-Westphalia","zip":"58455","country":"Germany","geoPoint":{"lat":51.44362,"lon":7.35258}},{"facility":"GSK Investigational Site","city":"Mainz","state":"Rhineland-Palatinate","zip":"55116","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"GSK Investigational Site","city":"Rhaunen","state":"Rhineland-Palatinate","zip":"55624","country":"Germany","geoPoint":{"lat":49.8638,"lon":7.34198}},{"facility":"GSK Investigational Site","city":"Dresden","state":"Saxony","zip":"01097","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"GSK Investigational Site","city":"Freiberg","state":"Saxony","zip":"09599","country":"Germany","geoPoint":{"lat":50.91089,"lon":13.33881}},{"facility":"GSK Investigational Site","city":"Leipzig","state":"Saxony","zip":"04315","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"GSK Investigational Site","city":"Pirna","state":"Saxony","zip":"01796","country":"Germany","geoPoint":{"lat":50.95843,"lon":13.93702}},{"facility":"GSK Investigational Site","city":"Köthen","state":"Saxony-Anhalt","zip":"06366","country":"Germany","geoPoint":{"lat":51.75185,"lon":11.97093}},{"facility":"GSK Investigational Site","city":"Magdeburg","state":"Saxony-Anhalt","zip":"39112","country":"Germany","geoPoint":{"lat":52.13129,"lon":11.63189}},{"facility":"GSK Investigational Site","city":"Lübeck","state":"Schleswig-Holstein","zip":"23554","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"10629","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"10717","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"10787","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"12157","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"12351","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Berlin","zip":"13347","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"GSK Investigational Site","city":"Hamburg","zip":"20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"GSK Investigational Site","city":"Hamburg","zip":"22143","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"GSK Investigational Site","city":"Hamburg","zip":"22415","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"GSK Investigational Site","city":"Kwun Tong","country":"Hong Kong","geoPoint":{"lat":22.31184,"lon":114.22176}},{"facility":"GSK Investigational Site","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"GSK Investigational Site","city":"Chieti","state":"Abruzzo","zip":"66013","country":"Italy","geoPoint":{"lat":42.34827,"lon":14.16494}},{"facility":"GSK Investigational Site","city":"Pescara","state":"Abruzzo","zip":"65100","country":"Italy","geoPoint":{"lat":42.4584,"lon":14.20283}},{"facility":"GSK Investigational Site","city":"Rome","state":"Lazio","zip":"00163","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"GSK Investigational Site","city":"Genoa","state":"Liguria","zip":"16132","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94439}},{"facility":"GSK Investigational Site","city":"Monza","state":"Lombardy","zip":"20052","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"GSK Investigational Site","city":"Cuneo","state":"Piedmont","zip":"12100","country":"Italy","geoPoint":{"lat":44.39071,"lon":7.54828}},{"facility":"GSK Investigational Site","city":"Cagliari","state":"Sardinia","zip":"09127","country":"Italy","geoPoint":{"lat":39.23054,"lon":9.11917}},{"facility":"GSK Investigational Site","city":"Sassari","state":"Sardinia","zip":"07100","country":"Italy","geoPoint":{"lat":40.72586,"lon":8.55552}},{"facility":"GSK Investigational Site","city":"Catania","state":"Sicily","zip":"95129","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"GSK Investigational Site","city":"Ragusa (RG)","state":"Sicily","zip":"97100","country":"Italy","geoPoint":{"lat":36.92574,"lon":14.72443}},{"facility":"GSK Investigational Site","city":"Fukuoka","zip":"810-0021","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"GSK Investigational Site","city":"Fukuoka","zip":"812-0025","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"GSK Investigational Site","city":"Fukuoka","zip":"813-8588","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"GSK Investigational Site","city":"Fukuoka","zip":"816-0864","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"GSK Investigational Site","city":"Kanagawa","zip":"224-8503","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"GSK Investigational Site","city":"Kanagawa","zip":"247-8533","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"GSK Investigational Site","city":"Kyoto","zip":"611-0041","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"GSK Investigational Site","city":"Tokyo","zip":"141-0001","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"GSK Investigational Site","city":"Tokyo","zip":"142-8666","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"GSK Investigational Site","city":"Tokyo","zip":"154-0024","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"GSK Investigational Site","city":"Zapopan, Jalisco","state":"Jalisco","zip":"45190","country":"Mexico"},{"facility":"GSK Investigational Site","city":"Cuernavaca","state":"Morelos","zip":"62210","country":"Mexico","geoPoint":{"lat":18.9261,"lon":-99.23075}},{"facility":"GSK Investigational Site","city":"Durango","zip":"34000","country":"Mexico","geoPoint":{"lat":24.02032,"lon":-104.65756}},{"facility":"GSK Investigational Site","city":"Monterrey","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"GSK Investigational Site","city":"Ansan","zip":"425-707","country":"South Korea","geoPoint":{"lat":37.365,"lon":127.46389}},{"facility":"GSK Investigational Site","city":"Bucheon-si","zip":"420-767","country":"South Korea","geoPoint":{"lat":37.49889,"lon":126.78306}},{"facility":"GSK Investigational Site","city":"Incheon","zip":"400-711","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"GSK Investigational Site","city":"Kangnam-gu, Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"GSK Investigational Site","city":"Kangwon-do","zip":"220-701","country":"South Korea"},{"facility":"GSK Investigational Site","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"GSK Investigational Site","city":"Seoul","zip":"150-950","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"GSK Investigational Site","city":"Seoul","zip":"152-703","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"GSK Investigational Site","city":"Alcover( Tarragona)","zip":"43460","country":"Spain","geoPoint":{"lat":41.26267,"lon":1.1701}},{"facility":"GSK Investigational Site","city":"Balenyà (Barcelona)","zip":"08550","country":"Spain"},{"facility":"GSK Investigational Site","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"GSK Investigational Site","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"GSK Investigational Site","city":"Centelles","country":"Spain","geoPoint":{"lat":41.79746,"lon":2.21902}},{"facility":"GSK Investigational Site","city":"La Roca Del Valles (Barcelona)","zip":"08430","country":"Spain","geoPoint":{"lat":41.58333,"lon":2.33333}},{"facility":"GSK Investigational Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"GSK Investigational Site","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"GSK Investigational Site","city":"Majadahonda","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"GSK Investigational Site","city":"Peralada( Girona)","zip":"17491","country":"Spain","geoPoint":{"lat":42.30823,"lon":3.0091}},{"facility":"GSK Investigational Site","city":"Valencia","zip":"46020","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"GSK Investigational Site","city":"Vic/ Barcelona","zip":"08500","country":"Spain"},{"facility":"GSK Investigational Site","city":"Borås","zip":"SE-506 30","country":"Sweden","geoPoint":{"lat":57.72101,"lon":12.9401}},{"facility":"GSK Investigational Site","city":"Eskilstuna","zip":"SE-631 88","country":"Sweden","geoPoint":{"lat":59.36661,"lon":16.5077}},{"facility":"GSK Investigational Site","city":"Gothenburg","zip":"SE-413 45","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"GSK Investigational Site","city":"Jönköping","zip":"SE-551 85","country":"Sweden","geoPoint":{"lat":57.78145,"lon":14.15618}},{"facility":"GSK Investigational Site","city":"Karlskrona","zip":"SE-371 41","country":"Sweden","geoPoint":{"lat":56.16156,"lon":15.58661}},{"facility":"GSK Investigational Site","city":"Linköping","zip":"SE-58758","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"facility":"GSK Investigational Site","city":"Malmö","zip":"SE-211 52","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"GSK Investigational Site","city":"Örebro","zip":"SE-703 62","country":"Sweden","geoPoint":{"lat":59.27412,"lon":15.2066}},{"facility":"GSK Investigational Site","city":"Skövde","zip":"SE-541 85","country":"Sweden","geoPoint":{"lat":58.39118,"lon":13.84506}},{"facility":"GSK Investigational Site","city":"Stockholm","zip":"SE-111 57","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"GSK Investigational Site","city":"Uppsala","zip":"SE-751 85","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"GSK Investigational Site","city":"Vällingby","zip":"SE-162 68","country":"Sweden","geoPoint":{"lat":59.36441,"lon":17.87407}},{"facility":"GSK Investigational Site","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"GSK Investigational Site","city":"Taipei","zip":"112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"GSK Investigational Site","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"GSK Investigational Site","city":"Taoyuan","zip":"333","country":"Taiwan","geoPoint":{"lat":24.99368,"lon":121.29696}},{"facility":"GSK Investigational Site","city":"Buckshaw Village, Chorley","state":"Lancashire","zip":"PR7 7NA","country":"United Kingdom","geoPoint":{"lat":53.65,"lon":-2.61667}},{"facility":"GSK Investigational Site","city":"Atherstone","state":"Warwickshire","zip":"CV9 1EU","country":"United Kingdom","geoPoint":{"lat":52.57536,"lon":-1.54693}},{"facility":"GSK Investigational Site","city":"Bradford on Avon","state":"Wiltshire","zip":"BA15 1DQ","country":"United Kingdom","geoPoint":{"lat":51.34772,"lon":-2.25065}},{"facility":"GSK Investigational Site","city":"Bangor","zip":"BT19 1PP","country":"United Kingdom","geoPoint":{"lat":54.66079,"lon":-5.66802}},{"facility":"GSK Investigational Site","city":"Belfast","zip":"BT7 2EB","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}},{"facility":"GSK Investigational Site","city":"Broughshane","zip":"BT42 4JP","country":"United Kingdom","geoPoint":{"lat":54.8926,"lon":-6.20899}},{"facility":"GSK Investigational Site","city":"Ledbury","zip":"HR8 2AA","country":"United Kingdom","geoPoint":{"lat":52.03639,"lon":-2.42635}},{"facility":"GSK Investigational Site","city":"Newtonabbey","zip":"BT37 9QW","country":"United Kingdom"},{"facility":"GSK Investigational Site","city":"Waterloo, Liverpool","zip":"L22 0LG","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"27626517","type":"BACKGROUND","citation":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800."},{"pmid":"29529222","type":"BACKGROUND","citation":"Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095."},{"type":"BACKGROUND","citation":"Ikematsu H et al. (2018) Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi. 92(2):103-114."},{"pmid":"29463421","type":"BACKGROUND","citation":"Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17."},{"pmid":"37166199","type":"DERIVED","citation":"Matthews S, Curran D, Sabater Cabrera E, Boutry C, Lecrenier N, Cunningham AL, Schmader K. An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of Placebo Patients From 3 Randomized Phase III Studies. Clin J Pain. 2023 Aug 1;39(8):386-393. doi: 10.1097/AJP.0000000000001129."},{"pmid":"36066965","type":"DERIVED","citation":"Kim JH, Johnson R, Kovac M, Cunningham AL, Amakrane M, Sullivan KM, Dagnew AF, Curran D, Schuind A. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. Pain. 2023 Apr 1;164(4):741-748. doi: 10.1097/j.pain.0000000000002760. Epub 2022 Aug 19."},{"pmid":"33606577","type":"DERIVED","citation":"Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, Leung EM, Tang H, Tsuru T, Watson P, Wu Z, Yu CJ, Yuan Y, Zahaf T, Cunningham AL, Schuind A. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults >/= 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021 Jul 3;17(7):2050-2057. doi: 10.1080/21645515.2020.1859321. Epub 2021 Feb 19."},{"pmid":"32910152","type":"DERIVED","citation":"Dagnew AF, Rausch D, Herve C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021 Mar 2;60(3):1226-1233. doi: 10.1093/rheumatology/keaa424."},{"pmid":"32347767","type":"DERIVED","citation":"Colindres R, Wascotte V, Brecx A, Clarke C, Herve C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020 Nov 1;16(11):2628-2633. doi: 10.1080/21645515.2020.1741312. Epub 2020 Apr 29."},{"pmid":"31537443","type":"DERIVED","citation":"Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, Schuind A; ZOE 50/70 study groups. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019 Oct 8;37(43):6262-6267. doi: 10.1016/j.vaccine.2019.09.028. Epub 2019 Sep 16."},{"pmid":"30935742","type":"DERIVED","citation":"Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29."},{"pmid":"29955836","type":"DERIVED","citation":"Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 Study Group. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1231-1238. doi: 10.1093/gerona/gly150."}],"seeAlsoLinks":[{"label":"IPD for this study will be made available via the Clinical Study Data Request site.","url":"https://clinicalstudydatarequest.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD for this study will be made available via the Clinical Study Data Request site.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://clinicalstudydatarequest.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Only 13900 subjects from the total enrolled number were vaccinated and included in the Total Vaccinated Cohort. In the placebo group,1 subject had an unknown withdrawal status before the study site closure. This was not identified during database freeze, leading to 1190 subjects in place of 1189 that actually completed the placebo group","groups":[{"id":"FG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"FG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6950"},{"groupId":"FG001","numSubjects":"6950"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5770"},{"groupId":"FG001","numSubjects":"5760"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1180"},{"groupId":"FG001","numSubjects":"1190"}]}],"dropWithdraws":[{"type":"Serious Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"456"},{"groupId":"FG001","numSubjects":"487"}]},{"type":"Non-Serious Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"387"},{"groupId":"FG001","numSubjects":"396"}]},{"type":"Migrated/moved from study area","reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"133"}]},{"type":"Suspected HZ Episode","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"No reason from the subject","reasons":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"Unknown completion status","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"BG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6950"},{"groupId":"BG001","value":"6950"},{"groupId":"BG002","value":"13900"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75.6","spread":"4.7"},{"groupId":"BG001","value":"75.6","spread":"4.7"},{"groupId":"BG002","value":"75.6","spread":"4.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3789"},{"groupId":"BG001","value":"3836"},{"groupId":"BG002","value":"7625"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3161"},{"groupId":"BG001","value":"3114"},{"groupId":"BG002","value":"6275"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Geographic ancestry","categories":[{"title":"African Heritage / African American","measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"146"}]},{"title":"American Indian or Alaskan Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"9"}]},{"title":"Asian - Central/South Asian Heritage","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"}]},{"title":"Asian - East Asian Heritage","measurements":[{"groupId":"BG000","value":"907"},{"groupId":"BG001","value":"908"},{"groupId":"BG002","value":"1815"}]},{"title":"Asian - Japanese Heritage","measurements":[{"groupId":"BG000","value":"298"},{"groupId":"BG001","value":"300"},{"groupId":"BG002","value":"598"}]},{"title":"Asian - South East Asian Heritage","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"White - Arabic / North African Heritage","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"87"}]},{"title":"White - Caucasian / European Heritage","measurements":[{"groupId":"BG000","value":"5307"},{"groupId":"BG001","value":"5301"},{"groupId":"BG002","value":"10608"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"304"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"610"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Any Episodes of Herpes Zoster (HZ)","description":"Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5114"},{"groupId":"OG001","value":"1427"},{"groupId":"OG002","value":"6541"},{"groupId":"OG003","value":"5189"},{"groupId":"OG004","value":"1433"},{"groupId":"OG005","value":"6622"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"169"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"223"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of vaccine efficacy in prevention of Herpes Zoster (HZ) disease between Zoster-022 GSK1437173A 70-79 YOA group and Zoster-022 Placebo 70-79 YOA group.","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of Herpes Zoster subunit (HZ/su) vaccine against herpes zoster disease was demonstrated if the lower limit (LL) of the two-sided 95% Confidence Interval (CI) of VE was above 10%.","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"90.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"83.54","ciUpperLimit":"94.32"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of vaccine efficacy in prevention of Herpes Zoster (HZ) disease between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against herpes zoster disease was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 10%","pValue":"<0.0001","statisticalMethod":"Poisson exact method","paramType":"Vaccine efficacy","paramValue":"89.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74.65","ciUpperLimit":"96.16"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of vaccine efficacy in prevention of Herpes Zoster (HZ) disease between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against herpes zoster disease was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 10%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"89.79","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"84.29","ciUpperLimit":"93.66"}]},{"type":"PRIMARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)","description":"Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6468"},{"groupId":"OG001","value":"1782"},{"groupId":"OG002","value":"8250"},{"groupId":"OG003","value":"6554"},{"groupId":"OG004","value":"1792"},{"groupId":"OG005","value":"8346"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"36"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of vaccine efficacy in prevention of Post-Herpetic Neuralgia (PHN) between Zoster-022/006 Pooled GSK1437173A 70-79YOA Group and Zoster-022/006 Pooled Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"93.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"72.47","ciUpperLimit":"99.19"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022/006 Pooled GSK1437173A \\>=80YOA Group and Zoster-022/006 Pooled Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"0.1844","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"71.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-51.51","ciUpperLimit":"97.08"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022/006 Pooled GSK1437173A \\>=70YOA Group and Zoster-022/006 Pooled Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"88.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68.70","ciUpperLimit":"97.10"}]},{"type":"PRIMARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ","description":"Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6468"},{"groupId":"OG001","value":"1782"},{"groupId":"OG002","value":"8250"},{"groupId":"OG003","value":"6554"},{"groupId":"OG004","value":"1792"},{"groupId":"OG005","value":"8346"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"216"},{"groupId":"OG004","value":"68"},{"groupId":"OG005","value":"284"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of vaccine efficacy in prevention of herpes zoster disease between Zoster-022/006 Pooled GSK1437173A 70-79YOA Group and Zoster-022/006 Pooled Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against herpes zoster disease was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 10%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"91.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"86.04","ciUpperLimit":"94.85"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of vaccine efficacy in prevention of herpes zoster disease between Zoster-022/006 Pooled GSK1437173A \\>=80YOA Group and Zoster-022/006 Pooled Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against herpes zoster disease was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 10%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"91.37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"80.22","ciUpperLimit":"96.94"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of vaccine efficacy in prevention of herpes zoster disease between Zoster-022/006 pooled GSK1437173A \\>=70 YOA Group and Zoster-022/006 Pooled Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against herpes zoster disease was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 10%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"91.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"86.88","ciUpperLimit":"94.46"}]},{"type":"SECONDARY","title":"Number of Subjects With Post-herpetic Neuralgia (PHN)","description":"PHN cases in the mTVc.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5114"},{"groupId":"OG001","value":"1427"},{"groupId":"OG002","value":"6541"},{"groupId":"OG003","value":"5189"},{"groupId":"OG004","value":"1433"},{"groupId":"OG005","value":"6622"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"28"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of of Vaccine Efficacy (VE) in prevention of PHN between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"90.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62.57","ciUpperLimit":"98.95"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"0.3072","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"65.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-91.58","ciUpperLimit":"96.62"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"<0.0001","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"85.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"58.52","ciUpperLimit":"96.30"}]},{"type":"SECONDARY","title":"Number of Days With Severe 'Worst' HZ-associated Pain","description":"Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"150"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"31.41"},{"groupId":"OG001","value":"98.7","spread":"57.73"},{"groupId":"OG002","value":"34.6","spread":"45.54"},{"groupId":"OG003","value":"47.9","spread":"100.08"},{"groupId":"OG004","value":"50.4","spread":"106.51"},{"groupId":"OG005","value":"48.5","spread":"101.40"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against duration of severe worst HZ associated pain was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.3749","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"21.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-34.40","ciUpperLimit":"54.39"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo\\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against duration of severe worst HZ associated pain was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.2466","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"51.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-65.55","ciUpperLimit":"85.95"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo\\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against duration of severe worst HZ associated pain was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.1877","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"28.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.69","ciUpperLimit":"56.44"}]},{"type":"SECONDARY","title":"Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations","description":"The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5114"},{"groupId":"OG001","value":"1427"},{"groupId":"OG002","value":"6541"},{"groupId":"OG003","value":"5189"},{"groupId":"OG004","value":"1433"},{"groupId":"OG005","value":"6622"}]}],"classes":[{"title":"Mortality","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hospitalization","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}]}]},{"title":"Mortality or hospitalization","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Overall Mortality and HZ-related Mortality","description":"The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5114"},{"groupId":"OG001","value":"1427"},{"groupId":"OG002","value":"6541"},{"groupId":"OG003","value":"5189"},{"groupId":"OG004","value":"1433"},{"groupId":"OG005","value":"6622"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Confirmed HZ Episode Related Hospitalizations","description":"Incidence of overall and HZ-related hospitalizations during the study.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5114"},{"groupId":"OG001","value":"1427"},{"groupId":"OG002","value":"6541"},{"groupId":"OG003","value":"5189"},{"groupId":"OG004","value":"1433"},{"groupId":"OG005","value":"6622"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction of overall and HZ related hospitalizations between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against overall and HZ related hospitalizations was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"0.2533","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-144.13","ciUpperLimit":"100.00"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction of overall and HZ related hospitalizations between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against overall and HZ related hospitalizations was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"0.5024","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-435.14","ciUpperLimit":"100.00"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction of overall and HZ related hospitalizations between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against overall and HZ related hospitalizations was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"0.0636","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.92","ciUpperLimit":"100.00"}]},{"type":"SECONDARY","title":"Number of Subjects With HZ Related Complications","description":"Incidence of HZ complications during the study in subjects with confirmed HZ.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"169"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"223"}]}],"classes":[{"title":"At least one complication","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"10"}]}]},{"title":"HZ vasculitis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Disseminated Disease","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Ophthalmic Disease","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"6"}]}]},{"title":"Neurologic Disease","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"}]}]},{"title":"Visceral Disease","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Stroke","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction of HZ related complications between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against HZ related complications was demonstrated if the LL of the VE was above 0%.","pValue":"0.4947","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"-65.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-827.06","ciUpperLimit":"73.62"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction of HZ related complications between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against HZ related complications was demonstrated if the LL of the VE was above 0%","pValue":"1.0000","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-558.05","ciUpperLimit":"100.00"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction of HZ related complications between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against HZ related complications was demonstrated if the LL of the VE was above 0%","pValue":"1.0000","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-433.32","ciUpperLimit":"83.16"}]},{"type":"SECONDARY","title":"Number of Subjects Receiving Pain Medication Associated With HZ","description":"Incidence of use of pain medications throughout the study","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"169"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"223"}]}],"classes":[{"title":"At least 1 pain medication","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"160"}]}]},{"title":"1 pain medication only","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"60"}]}]},{"title":"2 pain medications only","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"34"}]}]},{"title":"3 pain medications or more","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"66"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction in use of pain medication between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against use of pain medications was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"0.0112","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"43.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"10.77","ciUpperLimit":"70.53"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction in use of pain medication between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against use of pain medications was demonstrated if the LL of the two-sided 95% CI of the VE was above 0%","pValue":"0.3903","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"27.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-26.43","ciUpperLimit":"73.20"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction in use of pain medication between Zoster-022 GSK1437173A \\>=70YOA group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against use of pain medications was demonstrated if the LL of the two-sided 95% CI of VE was above 0%.","pValue":"0.0083","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"39.60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"10.79","ciUpperLimit":"64.75"}]},{"type":"SECONDARY","title":"Number of Days With Pain Medication Associated With HZ","description":"Incidence of reduction of duration of pain medication associated with HZ throughout the study.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 GSK1437173A >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022 GSK1437173A >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022 Placebo 70-79YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022 Placebo >=80YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022 Placebo >=70YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"160"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":"56.44"},{"groupId":"OG001","value":"274.7","spread":"337.00"},{"groupId":"OG002","value":"109.5","spread":"200.88"},{"groupId":"OG003","value":"218.6","spread":"593.80"},{"groupId":"OG004","value":"135.0","spread":"207.31"},{"groupId":"OG005","value":"199.3","spread":"530.60"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction in duration of pain medication associated with HZ between Zoster-022 GSK1437173A 70-79YOA Group and Zoster-022 Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against duration of pain medication associated with HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the hazard ratio was above 0%.","pValue":"0.0232","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"58.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11.45","ciUpperLimit":"80.96"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction in duration of pain medication associated with HZ between Zoster-022 GSK1437173A \\>=80YOA Group and Zoster-022 Placebo \\>=80YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against duration of pain medication associated with HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the hazard ratio was above 0%.","pValue":"0.8324","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"-14.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-303.30","ciUpperLimit":"67.46"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction in duration of pain medication associated with HZ between Zoster-022 GSK1437173A \\>=70YOA Group and Zoster-022 Placebo \\>=70YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"Efficacy of the HZ/su vaccine against duration of pain medication associated with HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the hazard ratio was above 0%.","pValue":"0.0404","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"49.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.92","ciUpperLimit":"73.47"}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","populationDescription":"The analysis was performed on the total vaccinated cohort - Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"classes":[{"title":"Any Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"26"}]}]},{"title":"Grade 3 Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"1"}]}]},{"title":"Any Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"3"}]}]},{"title":"Grade 3 Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3 Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"504"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"23"}]}]},{"title":"Grade 3 Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"3"}]}]},{"title":"Grade 3 Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"491"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"43"}]}]},{"title":"Grade 3 Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"1"}]}]},{"title":"Any Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"5"}]}]},{"title":"Grade 3 Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3 Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was performed on the total vaccinated cohort - Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"classes":[{"title":"Any Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"56"}]}]},{"title":"Grade 3 Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"34"}]}]},{"title":"Any Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}]}]},{"title":"Any Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"42"}]}]},{"title":"Grade 3 Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"27"}]}]},{"title":"Any Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"27"}]}]},{"title":"Grade 3 Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"17"}]}]},{"title":"Grade 3 Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Related Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"12"}]}]},{"title":"Any Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"9"}]}]},{"title":"Grade 3 Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"501"},{"groupId":"OG001","value":"503"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"4"}]}]},{"title":"Any Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"39"}]}]},{"title":"Grade 3 Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}]}]},{"title":"Related Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"30"}]}]},{"title":"Any Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"19"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Related Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}]}]},{"title":"Any Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"26"}]}]},{"title":"Grade 3 Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Related Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"20"}]}]},{"title":"Any Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"18"}]}]},{"title":"Grade 3 Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Related Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"11"}]}]},{"title":"Grade 3 Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Related Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"9"}]}]},{"title":"Any Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"6"}]}]},{"title":"Grade 3 Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"489"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"2"}]}]},{"title":"Any Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"77"}]}]},{"title":"Grade 3 Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"52"}]}]},{"title":"Any Gastrointestinal, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"40"}]}]},{"title":"Grade 3 Gastrointestinal, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Gastrointestinal, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"21"}]}]},{"title":"Any Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"55"}]}]},{"title":"Grade 3 Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"37"}]}]},{"title":"Any Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"41"}]}]},{"title":"Grade 3 Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"29"}]}]},{"title":"Any Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"22"}]}]},{"title":"Grade 3 Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"13"}]}]},{"title":"Grade 3 Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","populationDescription":"This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 30 days (Days 0-29) after each vaccination","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"title":"Any unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"3859"},{"groupId":"OG001","value":"2263"}]}]},{"title":"Grade 3 unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"265"}]}]},{"title":"Related unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"2853"},{"groupId":"OG001","value":"529"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 to Month 14","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"title":"Any SAE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"891"},{"groupId":"OG001","value":"939"}]}]},{"title":"Related SAE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Fatal Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"426"},{"groupId":"OG001","value":"459"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication","description":"The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated","populationDescription":"The analysis was based on the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"84"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)","description":"Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects","populationDescription":"This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"title":"Any pIMD","categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"97"}]}]},{"title":"Related pIMDs","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Medically Attended Visits","description":"Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.","populationDescription":"This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 to Month 8 post-vaccination","groups":[{"id":"OG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6950"},{"groupId":"OG001","value":"6950"}]}],"classes":[{"title":"Any medically attended visits","categories":[{"measurements":[{"groupId":"OG000","value":"2882"},{"groupId":"OG001","value":"2911"}]}]},{"title":"Related medically attended visits","categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"66"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA","description":"Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group","description":"Subjects between 50 and 59 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group","description":"Subjects between 60 and 69 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled GSK1437173A >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled GSK1437173A >=50 YOA Group","description":"Subjects above 50 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo 50-59 YOA Group","description":"Subjects between 50 and 59 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG006","title":"Zoster-022/006 Pooled Placebo 60-69 YOA Group","description":"Subjects between 60 and 69 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG007","title":"Zoster-022/006 Pooled Placebo 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG008","title":"Zoster-022/006 Pooled Placebo >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG009","title":"Zoster-022/006 Pooled Placebo >=50 YOA Group","description":"Subjects above 50 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3491"},{"groupId":"OG001","value":"2140"},{"groupId":"OG002","value":"6468"},{"groupId":"OG003","value":"1782"},{"groupId":"OG004","value":"13881"},{"groupId":"OG005","value":"3523"},{"groupId":"OG006","value":"2166"},{"groupId":"OG007","value":"6554"},{"groupId":"OG008","value":"1792"},{"groupId":"OG009","value":"14035"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"29"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"46"}]}]}],"analyses":[{"groupIds":["OG000","OG005"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022/006 Pooled GSK1437173A 50-59YOA Group and Zoster-022/006 Pooled Placebo 50-59YOA Group.Comparison of vaccine efficacy for groups 70-79 and above 80 YOA are presented in outcome measure 2.","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"0.0081","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"40.88","ciUpperLimit":"100.00"},{"groupIds":["OG001","OG006"],"groupDescription":"Comparison of vaccine efficacy in prevention of PHN between Zoster-022/006 Pooled GSK1437173A 60-69YOA Group and Zoster-022/006 Pooled Placebo 60-69YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine against PHN was demonstrated if the lower limit of the of the 2-sided 95% CI of VE was above 0%","pValue":"0.5097","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-442.83","ciUpperLimit":"100.00"}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ","description":"Occurrence of PHN during the entire study period in all subjects with confirmed HZ.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group","description":"Subjects between 50 and 59 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group","description":"Subjects between 60 and 69 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled GSK1437173A >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled GSK1437173A >=50 YOA Group","description":"Subjects above 50 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo 50-59 YOA Group","description":"Subjects between 50 and 59 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG006","title":"Zoster-022/006 Pooled Placebo 60-69 YOA Group","description":"Subjects between 60 and 69 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG007","title":"Zoster-022/006 Pooled Placebo 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG008","title":"Zoster-022/006 Pooled Placebo >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG009","title":"Zoster-022/006 Pooled Placebo >=50 YOA Group","description":"Subjects above 50 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"103"},{"groupId":"OG006","value":"90"},{"groupId":"OG007","value":"216"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"477"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"29"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"46"}]}]}],"analyses":[{"groupIds":["OG000","OG005"],"groupDescription":"Comparison of Vaccine efficacy in reduction of PHN incidence in subjects with confirmed HZ episode in Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group versus Zoster-022/006 Pooled Placebo 50-59 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine in reduction of PHN in subjects with confirmed HZ episodes was demonstrated if the LL of the two-sided 95% CI of VE was above 0%","pValue":"1.0000","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-649.86","ciUpperLimit":"100.00"},{"groupIds":["OG001","OG006"],"groupDescription":"Comparison of Vaccine efficacy in reduction of PHN incidence in subjects with confirmed HZ episode in Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group versus Zoster-022/006 Pooled Placebo 60-69 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine in reduction of PHN in subjects with confirmed HZ episodes was demonstrated if the LL of the two-sided 95% CI of VE was above 0%","pValue":"1.0000","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"100.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3938.70","ciUpperLimit":"100.00"},{"groupIds":["OG002","OG007"],"groupDescription":"Comparison of Vaccine efficacy in reduction of PHN incidence in subjects with confirmed HZ episode in Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group versus Zoster-022/006 Pooled Placebo 70-79 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine in reduction of PHN in subjects with confirmed HZ episodes was demonstrated if the LL of the two-sided 95% CI of VE was above 0%","pValue":"1.0000","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"21.60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-149.41","ciUpperLimit":"78.91"},{"groupIds":["OG003","OG008"],"groupDescription":"Comparison of Vaccine efficacy in reduction of PHN incidence in subjects with confirmed HZ episode in Zoster-022/006 Pooled GSK1437173A \\>=80 YOA Group versus Zoster-022/006 Pooled Placebo\\>=80 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine in reduction of PHN in subjects with confirmed HZ episodes was demonstrated if the LL of the two-sided 95% CI of VE was above 0%","pValue":"0.1528","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"-223.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-883.05","ciUpperLimit":"18.84"},{"groupIds":["OG004","OG009"],"groupDescription":"Comparison of Vaccine efficacy in reduction of PHN incidence in subjects with confirmed HZ episode in Zoster-022/006 Pooled GSK1437173A \\>=50 YOA Group versus Zoster-022/006 Pooled Placebo \\>=50 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The efficacy of HZ/su vaccine in reduction of PHN in subjects with confirmed HZ episodes was demonstrated if the LL of the two-sided 95% CI of VE was above 0%","pValue":"0.5417","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"0.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-161.53","ciUpperLimit":"65.57"}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.","description":"The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A >=70 YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled Placebo 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled Placebo >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo >=70 YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"216"},{"groupId":"OG004","value":"68"},{"groupId":"OG005","value":"284"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"61"},{"groupId":"OG005","value":"254"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022/006 pooled GSK1437173A 70-79YOA Group and Zoster-022/006 pooled Placebo 70-79YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The VE of HZ/su against duration of severe worst pain in subjects with confirmed HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.2885","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"23.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25.80","ciUpperLimit":"53.78"},{"groupIds":["OG001","OG004"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022/006 pooled GSK1437173A \\>=80 YOA Group and Zoster-022/006 pooled Placebo \\>=80 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The VE of HZ/su against duration of severe worst pain in subjects with confirmed HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.1940","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"54.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-50.03","ciUpperLimit":"86.46"},{"groupIds":["OG002","OG005"],"groupDescription":"Comparison of VE in reduction of duration of severe worst HZ associated pain between Zoster-022/006 pooled GSK1437173A \\>=70 YOA Group and Zoster-022/006 pooled Placebo\\>=70 YOA Group","nonInferiorityType":"OTHER","nonInferiorityComment":"The VE of HZ/su against duration of severe worst pain in subjects with confirmed HZ was demonstrated if the LL of the two-sided 95% CI of VE derived from the Hazard ratio was above 0%.","pValue":"0.1243","statisticalMethod":"Poisson exact test","paramType":"Vaccine efficacy","paramValue":"30.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.52","ciUpperLimit":"56.27"}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.","description":"Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.","populationDescription":"The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled GSK1437173A >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG002","title":"Zoster-022/006 Pooled GSK1437173A >=70 YOA Group","description":"Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG003","title":"Zoster-022/006 Pooled Placebo 70-79 YOA Group","description":"Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG004","title":"Zoster-022/006 Pooled Placebo >=80 YOA Group","description":"Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."},{"id":"OG005","title":"Zoster-022/006 Pooled Placebo >=70 YOA Group","description":"Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"61"},{"groupId":"OG005","value":"254"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":"29.71"},{"groupId":"OG001","value":"98.7","spread":"57.73"},{"groupId":"OG002","value":"32.1","spread":"43.80"},{"groupId":"OG003","value":"48.3","spread":"96.34"},{"groupId":"OG004","value":"45.2","spread":"95.58"},{"groupId":"OG005","value":"47.5","spread":"95.98"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","populationDescription":"The analysis was performed on the total vaccinated cohort - Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"classes":[{"title":"Any Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1336"},{"groupId":"OG001","value":"128"}]}]},{"title":"Grade 3 Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"1"}]}]},{"title":"Any Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"606"},{"groupId":"OG001","value":"17"}]}]},{"title":"Grade 3 Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"17"}]}]},{"title":"Grade 3 Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2246"},{"groupId":"OG001","value":"2255"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1241"},{"groupId":"OG001","value":"107"}]}]},{"title":"Grade 3 Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"3"}]}]},{"title":"Any Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"582"},{"groupId":"OG001","value":"14"}]}]},{"title":"Grade 3 Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"10"}]}]},{"title":"Grade 3 Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2160"},{"groupId":"OG001","value":"2169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1562"},{"groupId":"OG001","value":"199"}]}]},{"title":"Grade 3 Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"4"}]}]},{"title":"Any Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"851"},{"groupId":"OG001","value":"27"}]}]},{"title":"Grade 3 Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"519"},{"groupId":"OG001","value":"25"}]}]},{"title":"Grade 3 Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was performed on the total vaccinated cohort - Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"classes":[{"title":"Any Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"545"},{"groupId":"OG001","value":"231"}]}]},{"title":"Grade 3 Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"13"}]}]},{"title":"Related Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"147"}]}]},{"title":"Any Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"123"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}]},{"title":"Related Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"67"}]}]},{"title":"Any Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"189"}]}]},{"title":"Grade 3 Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]},{"title":"Related Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"132"}]}]},{"title":"Any Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"530"},{"groupId":"OG001","value":"159"}]}]},{"title":"Grade 3 Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"}]}]},{"title":"Related Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"101"}]}]},{"title":"Any Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"73"}]}]},{"title":"Grade 3 Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"}]}]},{"title":"Related Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"50"}]}]},{"title":"Any Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"34"}]}]},{"title":"Grade 3 Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2237"},{"groupId":"OG001","value":"2256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"579"},{"groupId":"OG001","value":"169"}]}]},{"title":"Grade 3 Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"116"}]}]},{"title":"Any Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"75"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}]},{"title":"Related Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"35"}]}]},{"title":"Any Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"133"}]}]},{"title":"Grade 3 Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"2"}]}]},{"title":"Related Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"86"}]}]},{"title":"Any Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"560"},{"groupId":"OG001","value":"112"}]}]},{"title":"Grade 3 Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"484"},{"groupId":"OG001","value":"75"}]}]},{"title":"Any Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"55"}]}]},{"title":"Grade 3 Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"4"}]}]},{"title":"Related Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"34"}]}]},{"title":"Any Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"30"}]}]},{"title":"Grade 3 Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Related Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2159"},{"groupId":"OG001","value":"2166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"14"}]}]},{"title":"Any Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"825"},{"groupId":"OG001","value":"326"}]}]},{"title":"Grade 3 Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"17"}]}]},{"title":"Related Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"220"}]}]},{"title":"Any Gastrointestinal, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"304"},{"groupId":"OG001","value":"172"}]}]},{"title":"Grade 3 Gastrointestinal,Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"10"}]}]},{"title":"Related Gastrointestinal,Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"91"}]}]},{"title":"Any Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"653"},{"groupId":"OG001","value":"268"}]}]},{"title":"Grade 3 Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"10"}]}]},{"title":"Related Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"547"},{"groupId":"OG001","value":"185"}]}]},{"title":"Any Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"790"},{"groupId":"OG001","value":"225"}]}]},{"title":"Grade 3 Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"10"}]}]},{"title":"Related Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"689"},{"groupId":"OG001","value":"157"}]}]},{"title":"Any Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"110"}]}]},{"title":"Grade 3 Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"6"}]}]},{"title":"Related Shivering, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"75"}]}]},{"title":"Any Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"61"}]}]},{"title":"Grade 3 Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Related Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2252"},{"groupId":"OG001","value":"2264"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"30"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA","description":"Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 30 days (Days 0 - 29) after each vaccination","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8758"},{"groupId":"OG001","value":"8773"}]}],"classes":[{"title":"Any unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"4366"},{"groupId":"OG001","value":"2732"}]}]},{"title":"Grade 3 unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"553"},{"groupId":"OG001","value":"335"}]}]},{"title":"Related unsolicited AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"2961"},{"groupId":"OG001","value":"578"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs","description":"Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.","populationDescription":"The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 to Month 14","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8758"},{"groupId":"OG001","value":"8773"}]}],"classes":[{"title":"Any SAE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"1171"}]}]},{"title":"Related SAE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs","description":"Fatal SAEs during the entire study period in subjects ≥ 70 YOA.","populationDescription":"The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8758"},{"groupId":"OG001","value":"8773"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"144"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs","description":"Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.","populationDescription":"The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8758"},{"groupId":"OG001","value":"8773"}]}],"classes":[{"title":"Any pIMD(s)","categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"118"}]}]},{"title":"Related pIMD(s)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits","description":"Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.","populationDescription":"The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 to Month 8 post-vaccination","groups":[{"id":"OG000","title":"Zoster-022/006 Pooled GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule."},{"id":"OG001","title":"Zoster-022/006 Pooled Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8758"},{"groupId":"OG001","value":"8773"}]}],"classes":[{"title":"Any medically attended visits","categories":[{"measurements":[{"groupId":"OG000","value":"3593"},{"groupId":"OG001","value":"3648"}]}]},{"title":"Related medically attended visits","categories":[{"measurements":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"80"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).","eventGroups":[{"id":"EG000","title":"Zoster-022 GSK1437173A Group","description":"Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.","deathsNumAffected":426,"deathsNumAtRisk":6950,"seriousNumAffected":1153,"seriousNumAtRisk":6950,"otherNumAffected":3067,"otherNumAtRisk":6950},{"id":"EG001","title":"Zoster-022 Placebo Group","description":"Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.","deathsNumAffected":459,"deathsNumAtRisk":6950,"seriousNumAffected":1214,"seriousNumAtRisk":6950,"otherNumAffected":610,"otherNumAtRisk":6950}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":6950}]},{"term":"Anaemia vitamin b12 deficiency","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Haemorrhagic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypersplenism","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Immune thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Microcytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Nephrogenic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Normochromic normocytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pernicious anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":6950}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":6950},{"groupId":"EG001","numEvents":29,"numAffected":28,"numAtRisk":6950}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Aortic valve disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Aortic valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Aortic valve stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":6950}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":40,"numAtRisk":6950},{"groupId":"EG001","numEvents":56,"numAffected":54,"numAtRisk":6950}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Bradyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":6950},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":6950}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":51,"numAtRisk":6950},{"groupId":"EG001","numEvents":62,"numAffected":57,"numAtRisk":6950}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cardiac failure chronic","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":6950},{"groupId":"EG001","numEvents":37,"numAffected":33,"numAtRisk":6950}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cardiac valve disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Cardiomegaly","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Chronotropic incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Congestive cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cor pulmonale","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":28,"numAtRisk":6950},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":6950}]},{"term":"Coronary artery insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Coronary artery occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Heart valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hypertensive heart disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ischaemic cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Left ventricular hypertrophy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Mitral valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":41,"numAtRisk":6950},{"groupId":"EG001","numEvents":45,"numAffected":45,"numAtRisk":6950}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":6950}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Sinus arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Tricuspid valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":6950}]},{"term":"Congenital cystic kidney disease","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypertrophic cardiomyopathy","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pyloric stenosis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Renal dysplasia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Sudden hearing loss","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vestibular disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cushingoid","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hyperparathyroidism primary","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Age-related macular degeneration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Amaurosis fugax","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Choroidal effusion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Iridocele","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Iritis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ocular hypertension","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ocular vascular disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Optic ischaemic neuropathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Retinal degeneration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Retinal haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Abdominal adhesions","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Abdominal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Abdominal strangulated hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Autoimmune pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Barrett's oesophagus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diaphragmatic hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diaphragmatic hernia, obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Diverticulum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Diverticulum intestinal haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6950}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Duodenal ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Enterovesical fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Faecal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gastric perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Gastritis haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gastrointestinal angiodysplasia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6950}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":6950}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Incarcerated inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Incarcerated umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":6950}]},{"term":"Inguinal hernia strangulated","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Intestinal infarction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Mallory-weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Mesenteric artery embolism","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Mesenteric artery thrombosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Mesenteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal spasm","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pancreatic disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":6950}]},{"term":"Peptic ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pharyngo-oesophageal diverticulum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Rectal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Rectal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Retroperitoneal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Salivary gland calculus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Thrombosis mesenteric vessel","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Accidental death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Administration site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Administration site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Adverse drug reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":6950}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":6950},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":6950}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":6950},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":6950}]},{"term":"Device battery issue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Device deposit issue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Device dislocation","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Device leakage","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Device occlusion","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Drowning","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ill-defined disorder","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Incarcerated hernia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":6950},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":6950}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Sudden cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thrombosis in device","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Acute hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Biliary dilatation","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":6950}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":6950},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":6950}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Chronic hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cirrhosis alcoholic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gallbladder perforation","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hepatic cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hepatitis alcoholic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ischaemic hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Allergic granulomatous angiitis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Amyloidosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Acarodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Alcaligenes infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Anal fistula infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anorectal cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Appendiceal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arteriosclerotic gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthritis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Biliary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":6950}]},{"term":"Bronchitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Candida sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cavernous sinus thrombosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":6950},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":6950}]},{"term":"Cholecystitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Clostridium bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Colonic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cystitis klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diabetic foot infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":6950}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Encephalitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Enterocolitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Epididymitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Escherichia infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Gastroenteritis clostridial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gastroenteritis salmonella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Graft infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Haematoma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Herpes zoster disseminated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Herpes zoster meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Herpes zoster oticus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Incision site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Infected dermal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Infectious colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intestinal gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Kidney infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Klebsiella bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Klebsiella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Labyrinthitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Liver abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Medical device site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Necrotising fasciitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Necrotising fasciitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Neuroborreliosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Ophthalmic herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Oropharyngeal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ovarian abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pancreatic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Peritonitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":70,"numAtRisk":6950},{"groupId":"EG001","numEvents":86,"numAffected":81,"numAtRisk":6950}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Postoperative abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Psittacosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Psoas abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Purulence","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Renal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Respiratory moniliasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":26,"numAtRisk":6950},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":6950}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":6950},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":6950}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Staphylococcal osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Streptococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":6950},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":6950}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":6950}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Vulvitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Back injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bone fissure","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Carbon monoxide poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Coronary artery reocclusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Coronary artery restenosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Deep vein thrombosis postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Eye penetration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Face injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":6950},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":6950}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Foreign body","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Incisional hernia","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Jaw fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Kidney contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":6950}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Limb crushing injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Multiple fractures","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Muscle rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Pneumothorax traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Post procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Post procedural pulmonary embolism","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Postoperative wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Procedural intestinal perforation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pubis fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Respiratory fume inhalation disorder","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Skin wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Spinal cord injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Spinal cord injury cervical","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Splenic rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Subdural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Synovial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Traumatic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Traumatic intracranial haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Vascular graft occlusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vascular pseudoaneurysm","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Wound evisceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Wound haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Blood glucose fluctuation","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Heart rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lactic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Marasmus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Uraemic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acquired claw toe","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthrofibrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cervical spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chondrocalcinosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chondropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gouty arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intervertebral disc disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Meniscal degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Mixed connective tissue disease","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":6950},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":6950}]},{"term":"Osteochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Osteoporotic fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Polymyalgia rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Polymyositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pseudarthrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Rheumatoid arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Sjogren's syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Spinal column stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Spondyloarthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Still's disease adult onset","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Synovial cyst","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Synovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Systemic lupus erythematosus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Tenosynovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Trigger finger","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Acral lentiginous melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute monocytic leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Adenocarcinoma gastric","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Adenocarcinoma pancreas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Adrenal adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Adrenal gland cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anaplastic astrocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anaplastic thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"B precursor type acute leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Benign neoplasm of thyroid gland","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Benign ovarian tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bile duct cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":6950}]},{"term":"Bladder cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bladder neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Bladder papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Bladder transitional cell carcinoma recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bone cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bowen's disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Brain neoplasm benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Bronchial carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Carcinoid tumour pulmonary","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Central nervous system neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cholangiocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Cholesteatoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Chronic lymphocytic leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chronic myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Colon adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Colon cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Colon neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Diffuse large b-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Diffuse large b-cell lymphoma stage iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Endometrial adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Fallopian tube cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Follicular thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Gallbladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Gastrointestinal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Gastrointestinal tract adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Glioblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Glioblastoma multiforme","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hepatic cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Hepatic cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hepatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hepatocellular carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypergammaglobulinaemia benign monoclonal","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intestinal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Invasive lobular breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Invasive papillary breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Large cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Large intestine benign neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Laryngeal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Lung adenocarcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Lung adenocarcinoma stage iii","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Lung neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":6950},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":6950}]},{"term":"Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Malignant fibrous histiocytoma of bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Malignant lymphoma unclassifiable high grade","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Malignant mast cell neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Malignant neoplasm of ampulla of vater","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Malignant palate neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Mesothelioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Metastases to adrenals","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Metastases to gastrointestinal tract","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastases to liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Metastases to lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastases to lymph nodes","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastases to peritoneum","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Metastases to stomach","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Metastasis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastatic carcinoma of the bladder","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastatic gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Metastatic malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Metastatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Metastatic renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Metastatic squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Neoplasm prostate","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Non-hodgkin's lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Non-small cell lung cancer stage iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Oesophageal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Oesophageal adenocarcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Oesophageal cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Oesophageal squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ovarian cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ovarian epithelial cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Ovarian germ cell teratoma benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":6950}]},{"term":"Pancreatic carcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Pancreatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pancreatic neuroendocrine tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Paraganglion neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Parathyroid tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pituitary tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":6950},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":6950}]},{"term":"Prostate cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Prostate cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Prostate cancer stage iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Prostatic adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Rectal cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Renal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Renal cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Renal cell carcinoma recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Renal oncocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Salivary gland cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Sarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Skin cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Small cell lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Small intestine adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Squamous cell carcinoma of lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Squamous cell carcinoma of the oral cavity","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Sweat gland tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"T-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Throat cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Tongue neoplasm malignant stage unspecified","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Transitional cell carcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Urethral neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Vulval cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Amyotrophic lateral sclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Basal ganglia haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Basilar artery thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Brain injury","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Brain stem infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Brain stem syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Carotid artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Carotid sinus syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Central nervous system lesion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cerebellar haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Cerebellar ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cerebral artery embolism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cerebral artery thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cerebral atrophy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":6950},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":6950}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Cerebrospinal fluid leakage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":34,"numAtRisk":6950},{"groupId":"EG001","numEvents":33,"numAffected":31,"numAtRisk":6950}]},{"term":"Cerebrovascular disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Cervical myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Dementia alzheimer's type","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Dementia with lewy bodies","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diabetic coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Drop attacks","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dural arteriovenous fistula","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dyspraxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Guillain-barre syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypertonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hypoxic-ischaemic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intraventricular haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lumbar radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Miller fisher syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Mixed dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Myasthenia gravis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Myoclonus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Nerve compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Parkinson's disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Parkinsonism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Post herpetic neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Progressive supranuclear palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Senile dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Spondylitic myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":6950},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":6950}]},{"term":"Thalamic infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thalamus haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Thrombotic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Transient global amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":6950},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":6950}]},{"term":"Trigeminal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Vascular dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vertebrobasilar insufficiency","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Viiith nerve lesion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Viith nerve paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Abnormal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Affective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Alcohol withdrawal syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Breathing-related sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Mental disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Mental disorder due to a general medical condition","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Panic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Schizoaffective disorder bipolar type","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Somatoform disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":6950},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":6950}]},{"term":"Acute prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bladder neck obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bladder perforation","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Bladder prolapse","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":6950}]},{"term":"Cystitis haemorrhagic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Cystitis interstitial","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Glomerulonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Nephroangiosclerosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Nephropathy toxic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Neurogenic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Renal disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":6950},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":6950}]},{"term":"Renal hypertension","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Renal mass","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Urethral haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Urethral meatus stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Urethral stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Urinary tract disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Atrophic vulvovaginitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":6950}]},{"term":"Breast dysplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Prostatic obstruction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Prostatomegaly","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Rectocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Uterine polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Uterine prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Vaginal prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vaginal ulceration","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":6950}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":6950},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":6950}]},{"term":"Diaphragmatic disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hyperventilation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Nasal septum deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Pulmonary cavitation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":6950},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":6950}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":6950},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":6950}]},{"term":"Actinic keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Dermatomyositis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Lichen planus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Skin necrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Stasis dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Hospitalisation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Rectal polypectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Aneurysm ruptured","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Aortic aneurysm rupture","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Aortic arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Aortic dissection","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Aortic occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Aortic rupture","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":6950}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":6950}]},{"term":"Arteriovenous fistula","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Blood pressure inadequately controlled","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":6950}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Femoral artery aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Femoral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6950}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":6950},{"groupId":"EG001","numEvents":27,"numAffected":25,"numAtRisk":6950}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Hypertensive emergency","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":6950}]},{"term":"Inferior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Intermittent claudication","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Internal haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Labile hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Microscopic polyangiitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Necrosis ischaemic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6950}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":6950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":6950}]},{"term":"Peripheral artery aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Peripheral artery stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Temporal arteritis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thromboangiitis obliterans","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6950}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6950}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6950}]}],"otherEvents":[{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":415,"numAffected":353,"numAtRisk":6950},{"groupId":"EG001","numEvents":46,"numAffected":39,"numAtRisk":6950}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":592,"numAffected":474,"numAtRisk":6950},{"groupId":"EG001","numEvents":192,"numAffected":169,"numAtRisk":6950}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":717,"numAffected":586,"numAtRisk":6950},{"groupId":"EG001","numEvents":307,"numAffected":243,"numAtRisk":6950}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1150,"numAffected":864,"numAtRisk":6950},{"groupId":"EG001","numEvents":29,"numAffected":27,"numAtRisk":6950}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2762,"numAffected":1975,"numAtRisk":6950},{"groupId":"EG001","numEvents":165,"numAffected":148,"numAtRisk":6950}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":773,"numAffected":613,"numAtRisk":6950},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":6950}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":472,"numAffected":378,"numAtRisk":6950},{"groupId":"EG001","numEvents":113,"numAffected":99,"numAtRisk":6950}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":669,"numAffected":428,"numAtRisk":6950},{"groupId":"EG001","numEvents":67,"numAffected":60,"numAtRisk":6950}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":633,"numAffected":535,"numAtRisk":6950},{"groupId":"EG001","numEvents":56,"numAffected":52,"numAtRisk":6950}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D006562","term":"Herpes Zoster"}],"ancestors":[{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}